<DOC>
	<DOCNO>NCT00301847</DOCNO>
	<brief_summary>This phase II trial study well sorafenib work treat patient kidney cancer spread brain . Sorafenib may stop growth tumor cell block enzymes need cell growth block blood flow tumor .</brief_summary>
	<brief_title>Sorafenib Treating Patients With Kidney Cancer That Has Spread Brain</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine partial minor response rate patient renal cell carcinoma ( RCC ) metastatic brain treat sorafenib . SECONDARY OBJECTIVES : I . Determine toxicity sorafenib patient RCC metastatic brain . II . Determine whether effect sorafenib RCC metastatic brain similar effect non-brain metastatic site . OUTLINE : This multicenter study . Patients receive oral sorafenib twice daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm renal cell carcinoma metastatic brain Measurable disease brain Meets 1 follow criterion : No prior brainspecific therapy AND CNS symptom referable brain lesion ( ) ( without concurrent steroid therapy ) CNS symptom referable brain lesion ( ) AND receive primary therapy brain lesion ( ) PATIENT CHARACTERISTICS : Blood pressure &lt; 140/90 mm Hg 2 separate occasion , take least 24 hour apart , within past 6 week ( patient stable antihypertensive regimen allow ) ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % Bilirubin &lt; 1.5 time upper limit normal ( ULN ) ALT/AST &lt; 2.5 time ULN Estimated glomerular filtration rate &gt; 30 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able swallow pill comply oral treatment regimen No history bleed diathesis requirement fulldose anticoagulation No history allergic reaction attribute compound similar chemical biologic composition sorafenib No clinical radiologic evidence bowel obstruction perforation No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit compliance study requirement PRIOR CONCURRENT THERAPY : More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) recover More 4 week since prior radiotherapy site outside brain recover More 8 week since prior standard externalbeam radiotherapy brain unless evidence inbrain progression No prior complete surgical resection radiosurgery know brain metastasis unless evidence inbrain progression No prior sorafenib , sunitinib malate , bevacizumab , agent target plateletderived growth factor receptor ( PDGFR ) vascular endothelial growth factor receptor ( VEGFR ) kinase cascade No concurrent investigational agent No concurrent enzymeinducing antiseizure medication , include phenytoin , phenobarbital , carbamazepine , primidone Concurrent nonenzymeinducing antiseizure medication allow No concurrent combination antiretroviral therapy HIVpositive patient No concurrent hematopoietic growth factor except erythropoietin No concurrent ketoconazole , itraconazole , ritonavir No concurrent grapefruit juice No concurrent Hypericum perforatum ( St. John 's wort ) No concurrent chemotherapy No concurrent hormonal therapy except steroid adrenal failure and/or control CNS edema hormone nondisease related condition ( e.g. , insulin diabetes ) No concurrent palliative radiotherapy No concurrent anticancer therapy Concurrent bisphosphonates allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>tumor metastatic brain</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>